Metformin and heart failure: never say never again
Open accessAbstract
Metformin represents the cornerstone of treatment for type 2 diabetes mellitus. Traditionally, heart failure (HF) was considered a contraindication to its use. However, more recent evidence has shown that this should no longer be the case. Indeed, studies have demonstrated that metformin may even reduce the risk of incident HF and mortality in diabetic patients, while improving up to 2-year survival rates in those with HF. In addition, it appears to exert cardioprotective actions. Although longer follow-up data and more explicit information about the situation in patients with very advanced HF are needed, the cardiac safety of metformin has profound clinical implications and may be anticipated to further encourage its widespread use.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several retrospective studies in patients with congestive heart failure and diabetes reported lower risk of death from any cause, lower hospital readmissions for congestive heart failure, and hospitalizations for any cause.
“Several retrospective studies in patients with CHF and diabetes reported lower risk of death from any cause [81-83], lower hospital readmissions for CHF [81], and hospitalizations for any cause [81,82].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [83]
A recent review concluded that congestive heart failure could not be considered an absolute contraindication for metformin use and suggests its protective effect in reducing the incidence of congestive heart failure and mortality in type 2 diabetes mellitus.
“A recent review concluded that CHF could not be considered an absolute contraindication for metformin use and also suggest its protective effect in reducing the incidence of CHF and mortality in T2DM [83].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · see citing works
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · see citing works
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · see citing works
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880 · see citing works
Bolen, S. D., Feldman, L. S., Vassy, J. L., Wilson, L. M., Yeh, H., Marinopoulos, S. S., Wiley, C., Selvin, E., Wilson, R. F., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 816 · see citing works
Xie, Z., Lau, K., Eby, B., Lozano, P., He, C., Pennington, B., Li, H., Rathi, S., Dong, Y., Tian, R., et al. (2011) · Diabetes · doi:10.2337/db10-0351 · Cited by 490 · see citing works
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458 · see citing works
Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444 · see citing works
Calvert, J. W., Gundewar, S., Jha, S., Greer, J. J. M., Bestermann, W. H., Tian, R., & Lefer, D. J. (2008) · Diabetes · doi:10.2337/db07-1098 · Cited by 422 · see citing works
Gundewar, S., Calvert, J. W., Jha, S. K., Toedt‐Pingel, I., Ji, S. Y., Nunez, D. J., Ramachandran, A., Anaya-Cisneros, M., Tian, R., & Lefer, D. J. (2008) · Circulation Research · doi:10.1161/circresaha.108.190918 · Cited by 422 · see citing works
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421 · see citing works
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2345 · Cited by 419 · see citing works
Eurich, D. T., McAlister, F. A., Blackburn, D. F., Majumdar, S. R., Tsuyuki, R. T., Varney, J., & Johnson, J. A. (2007) · BMJ · doi:10.1136/bmj.39314.620174.80 · Cited by 360 · see citing works
Roussel, R. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.409 · Cited by 356 · see citing works
Essential Role of Smad3 in Infarct Healing and in the Pathogenesis of Cardiac Remodeling
Bujak, M., Ren, G., Kweon, H. J., Dobaczewski, M. P., Reddy, A. K., Taffet, G. E., Wang, X.-F., & Frangogiannis, N. G. (2007) · Circulation · doi:10.1161/circulationaha.107.704197 · Cited by 356 · see citing works
Metformin Prevents Progression of Heart Failure in Dogs
Sasaki, H., Asanuma, H., Fujita, M., Takahama, H., Wakeno, M., Ito, S., Ogai, A., Asakura, M., Kim, J., Minamino, T., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.798561 · Cited by 287 · see citing works
Metformin attenuates cardiac fibrosis by inhibiting the TGFβ1–Smad3 signalling pathway
Xiao, H., Ma, X., Feng, W., Fu, Y., Lü, Z., Xu, M., Shen, Q., Zhu, Y., & Zhang, Y. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq066 · Cited by 231 · see citing works
Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure
Aguilar, D. A., Chan, W., Bozkurt, B., Ramasubbu, K., & Deswal, A. M. (2010) · Circulation Heart Failure · doi:10.1161/circheartfailure.110.952556 · Cited by 204 · see citing works
Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure
Yin, M., van der Horst, I. C. C., van Melle, J. P., Cheng, Q., van Gilst, W. H., Silljé, H. H. W., & de Boer, R. A. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00054.2011 · Cited by 170 · see citing works
Contraindications can damage your health—is metformin a case in point?
Holstein, A., & Stümvoll, M. (2005) · Diabetologia · doi:10.1007/s00125-005-0026-1 · Cited by 165 · see citing works
Andersson, C., Olesen, J. B., Hansen, P. R., Weeke, P. E., Norgaard, M. L., Jørgensen, C. H., Lange, T., Abildstrom, S. Z., Schramm, T. K., Vaag, A. A., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1906-6 · Cited by 154 · see citing works
MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D., Bhagra, S., Jhund, P. S., Petrie, M. C., McMurray, J. J. V., Petrie, J. R., & McAlister, F. A. (2010) · Diabetes Care · doi:10.2337/dc09-2227 · Cited by 149 · see citing works
Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?
Tahrani, A. A., Varughese, G. I., Scarpello, J. H., & Hanna, F. W. F. (2007) · BMJ · doi:10.1136/bmj.39255.669444.ae · Cited by 138 · see citing works
Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure
Masoudi, F. A., Wang, Y., Inzucchi, S. E., Setaro, J. F., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2003) · JAMA · doi:10.1001/jama.290.1.81 · Cited by 133 · see citing works
Contra‐indications to metformin therapy are largely disregarded
Holstein, A., Nahrwold, D. A., Hinze, S., & EGBERTS, E. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00115.x · Cited by 131 · see citing works
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0090-3 · Cited by 123 · see citing works
Fischer, Y., Thomas, J., Rosen, P., & Kammermeier, H. (1995) · Endocrinology · doi:10.1210/endo.136.2.7835271 · Cited by 114 · see citing works
The Risk of Heart Failure in Patients with Type 2 Diabetes Treated with Oral Agent Monotherapy
McAlister, F. A., Eurich, D. T., Majumdar, S. R., & Johnson, J. A. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.05.013 · Cited by 103 · see citing works
Should Physicians Address Patients' Spiritual Needs?
Catlin, E. A. (2002) · JAMA · doi:10.1001/jama.287.19.2502 · Cited by 102 · see citing works
Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction
Inzucchi, S. E., Masoudi, F. A., Wang, Y., Kosiborod, M., Foody, J. M., Setaro, J. F., Havranek, E. P., & Krumholz, H. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1680 · Cited by 101 · see citing works
Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and Diabetes
Shah, D. D., Fonarow, G. C., & Horwich, T. B. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.10.022 · Cited by 100 · see citing works
Effect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus
Evans, J. M. M., Doney, A. S. F., AlZadjali, M. A., Ogston, S. A., Petrie, J. R., Morris, A. D., Struthers, A. D., Wong, A., & Lang, C. C. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.05.031 · Cited by 93 · see citing works
Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?
Nye, H. J., & Herrington, W. G. (2011) · Nephron Clinical Practice · doi:10.1159/000323739 · Cited by 92 · see citing works
Pioglitazone initiation and subsequent hospitalization for congestive heart failure
Karter, A., Ahmed, A., Liu, J., Moffet, H. M., & Parker, M. M. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01704.x · Cited by 90 · see citing works
Metformin improves cardiac function in rats via activation of AMP‐activated protein kinase
Wang, X., Zhang, J., Li, L., Zhao, X., Tao, H., & Zhang, L. (2010) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2010.05470.x · Cited by 89 · see citing works
Maru, S., Koch, G. G., Stender, M., Clark, D., Gibowski, L., Petri, H., White, A., & Simpson, R. J. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.20 · Cited by 86 · see citing works
Metformin's contraindications should be contraindicated
McCormack, J. P. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045292 · Cited by 76 · see citing works
Frequency of Inappropriate Metformin Prescriptions
Horlen, C. K., Malone, R., Bryant, B., Dennis, B., Carey, T., Pignone, M., & Rothman, R. (2002) · JAMA · doi:10.1001/jama.287.19.2504-a · Cited by 76 · see citing works
Metformin: safety in cardiac patients
Khurana, R., & Malik, I. S. (2009) · Postgraduate Medical Journal · doi:10.1136/hrt.2009.173773 · Cited by 68 · see citing works
Inzucchi, S. E., Masoudi, F. A., & McGuire, D. K. (2007) · Diabetes Care · doi:10.2337/dc07-1686 · Cited by 64 · see citing works
Forcheron, F., Basset, A., Abdallah, P., del Carmine, P., Gadot, N., & Beylot, M. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-16 · Cited by 58 · see citing works
Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality
Eurich, D. T., Tsuyuki, R. T., Majumdar, S. R., McAlister, F. A., Lewanczuk, R. Z., Shibata, M. C., & Johnson, J. A. (2009) · Trials · doi:10.1186/1745-6215-10-12 · Cited by 54 · see citing works
Inzucchi, S. E. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2585 · Cited by 39 · see citing works
Metformin: diamonds are forever
Παπάνας, Ν., Maltezos, E. S., & Mikhailidis, D. P. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903176453 · Cited by 34 · see citing works
Self-citationOral Antidiabetic Therapy in Patients with Heart Disease
Fisman, E. Z., Tenenbaum, A., Motro, M., & Adler, Y. (2004) · Herz · doi:10.1007/s00059-004-2476-5 · Cited by 30 · see citing works
Metformin-Associated Lactic Acidosis Precipitated by Acute Renal Failure
Shenoy, C. (2006) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200601000-00016 · Cited by 29 · see citing works
Khurana, R., & Malik, I. S. (2009) · Cited by 28 · see citing works
Koro, C. E., Bowlin, S. J., & Weiss, S. R. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1069 · Cited by 26 · see citing works
Metformin's contraindications: needed for now
Fantus, I. G. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050401 · Cited by 20 · see citing works
Casscells, S. W., Granger, E., Swedorske, J., Goldhammer, R., Shaheen, M., Dorris, J., Hong, A., & Wiktor, M. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817534d5 · Cited by 12 · see citing works
Metformin Use in Decompensated Heart Failure
Boyd, A., & Nawarskas, J. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e3181846c53 · Cited by 9 · see citing works
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., Yasui, Y., & Johnson, J. A. (2010) · PubMed Central · Cited by 7 · see citing works
Metformin and Heart Failure: Innocent Until Proven Guilty
Muntoni, S. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-2259 · Cited by 7 · see citing works
Παπάνας, Ν., Monastiriotis, C., Christakidis, D., & Maltezos, E. S. (2009) · Acta Clinica Belgica · doi:10.1179/acb.2009.008 · Cited by 6 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567 · see citing works
Scheen, A. J., & Paquot, N. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.02.006 · Cited by 171 · see citing works
Metformin as a geroprotector: experimental and clinical evidence
Piskovatska, V., Stefanyshyn, N., Storey, K. B., Vaiserman, A. M., & Lushchak, O. V. (2018) · Biogerontology · doi:10.1007/s10522-018-9773-5 · Cited by 109 · see citing works
Renoprotective Effects of Metformin
Broe, M. E. D., Kajbaf, F., & Lalau, J. (2017) · The Nephron journals/Nephron journals · doi:10.1159/000481951 · Cited by 83 · see citing works
Cicero, A. F. G., Tartagni, E., & Ertek, S. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.31622 · Cited by 82 · see citing works
Metformin raises hydrogen sulfide tissue concentrations in various mouse organs
Wiliński, B., Wiliński, J., Somogyi, E., Piotrowska, J., & Opoka, W. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71053-3 · Cited by 67 · see citing works
Health Benefits of Anti-aging Drugs
Piskovatska, V., Strilbytska, O. M., Koliada, A. K., Vaiserman, A. M., & Lushchak, O. V. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_13 · Cited by 62 · see citing works
Yandrapalli, S., Jolly, G., Horblitt, A., Sanaani, A., & Aronow, W. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1358064 · Cited by 50 · see citing works
Epigenetic Therapies for Heart Failure: Current Insights and Future Potential
Claudio Napoli, A., Bontempo, P., Palmieri, V., Coscioni, E., Maiello, C., Donatelli, F., & Benincasa, G. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s287082 · Cited by 43 · see citing works
Sudden cardiac death and diabetes mellitus
Vasiliadis, I. K., Kolovou, G. D., Mavrogeni, S. I., Nair, D. R., & Mikhailidis, D. P. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.02.003 · Cited by 34 · see citing works
Self-citationFungal central nervous system infections: prevalence and diagnosis
Kourbeti, I. S., & Mylonakis, E. E. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.874282 · Cited by 30 · see citing works
Metformin in heart failure patients
Kinsara, A. J., & Ismail, Y. (2017) · Indian Heart Journal · doi:10.1016/j.ihj.2017.05.009 · Cited by 27 · see citing works
Tasimelteon for treating non-24-h sleep-wake rhythm disorder
Nishimon, S., Nishimon, M., & Nishino, S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1603293 · Cited by 24 · see citing works
Personalizing guidelines for diabetes management: twilight or dawn of the expert?
Paschou, S. Α., & Leslie, R. D. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-161 · Cited by 22 · see citing works
Sciannimanico, S. M., Grimaldi, F., Vescini, F., Pergola, G. D., Iacoviello, M., Licchelli, B., Guastamacchia, E., Giagulli, V. A., & Triggiani, V. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190507125847 · Cited by 20 · see citing works
Lepelley, M., Giai, J., Yahiaoui, N., Chanoine, S., & Villier, C. (2016) · Journal of Diabetes Research · doi:10.1155/2016/3545914 · Cited by 18 · see citing works
Berberine protects against metformin-associated lactic acidosis in induced diabetes mellitus.
Almani, S. A., Memon, I. A., Shaikh, T. Z., Khoharo, H. K., & Ujjan, I. (2017) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2017.8675 · Cited by 18 · see citing works
Katsiki, N., Ferrannini, E., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154218 · Cited by 18 · see citing works
Advances in the pharmacological management of non-24-h sleep-wake disorder
Nishimon, S., Nishino, N., & Nishino, S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1876665 · Cited by 14 · see citing works
Multidimensional effects of metformin in patients with type 2 diabetes
Ruyatkina, L. A., & Ruyatkin, D. S. (2016) · Diabetes Mellitus · doi:10.14341/dm2003458-64 · Cited by 12 · see citing works
Safety of lacosamide in children with refractory partial epilepsy
Pasha, I., Kamate, M., & Suresh, D. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2015.01.006 · Cited by 10 · see citing works
Norwood, D. K., Chilipko, A. A., Amin, S. M., Macharia, D., & Still, K. L. (2013) · The Consultant Pharmacist · doi:10.4140/tcp.n.2013.579 · Cited by 10 · see citing works
Salber, G. J., Wang, Y.-B., Lynch, J. T., Pasquale, K. M., Rajan, T. V., Stevens, R. G., Grady, J. J., & Kenny, R. A. (2017) · Clinical Diabetes · doi:10.2337/cd15-0045 · Cited by 9 · see citing works
Heart failure and diabetes mellitus: insight into comorbidity
Petunina, N. A., Викторович, Т. И., Trukhina, L. V., Sizova, Z. M., & Zakharova, V. L. (2019) · Diabetes Mellitus · doi:10.14341/dm9784 · Cited by 8 · see citing works
Renoprotective effects of metformin
Nasri, H. (2013) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-21-36 · Cited by 8 · see citing works
Huang, W.-X., & Zhao, R. (2024) · Endocrine · doi:10.1007/s12020-024-04025-6 · Cited by 7 · see citing works
Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes
Katsiki, N., Kazakos, K., & Triposkiadis, F. K. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2143263 · Cited by 6 · see citing works
Ertugliflozin + metformin as a treatment option for type 2 diabetes
Athyros, V. G., Boutari, C., & Karagiannis, A. I. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1939676 · Cited by 5 · see citing works
Ritsinger, V., Hagström, E., Hambræus, K., James, S. K., Jernberg, T., Lagerqvist, B., Leósdóttir, M., Lundman, P., Pernow, J., Östlund, O., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108599 · Cited by 3 · see citing works
Nardi, E., Prastaro, M., Santoro, C., Gallo, L., Simeoli, L., Fontanarosa, S., Paolillo, S., Gargiulo, P., Esposito, G., & Filardi, P. P. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104033 · Cited by 2 · see citing works
Metformin: od mehanizmov delovanja do napredne klinične uporabe
Janić, M., Volčanšek, Š., Lunder, M., & Janež, A. (2017) · Slovenian Medical Journal · doi:10.6016/zdravvestn.1503 · Cited by 3 · see citing works
Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin
Petunina, N. A., & Терехова, А. Л. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-21-138-145 · Cited by 1 · see citing works
Francoeur, R. B. (2021) · Mathematics · doi:10.3390/math9212715 · Cited by 1 · see citing works
Lepelley, M. (2013) · OpenGrey (Institut de l'Information Scientifique et Technique)
Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban
DiNicolantonio, J. J., Tomek, A., Meier, P., O’Keefe, J. H., D’Ascenzo, F., Cerrato, E., Chatterjee, S., & Biondi‐Zoccai, G. (2014) · Open Heart · doi:10.1136/openhrt-2014-000134
Вацеба, Т. С. (2017) · Bukovinian Medical Herald · doi:10.24061/2413-0737.xxi.2.82.1.2017.1
Reducing the risk of heart failure in diabetes mellitus: review of new therapeutics
Godbole, S., & Godbole, S. V. (2020) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20201094 · Cited by 1 · see citing works
(2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328360f5be
Doehner, W., Friede, T., Edelmann, F., Landmesser, U., Winkler, S., Pieske, B. M., Knebel, F., Kelle, S., Tschöpe, D., Meyer, A., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.89
- Authors
- Papanas, N., Maltezos, E., & Mikhailidis, D. P.
- Affiliations
- Democritus University of Thrace (GR)
- The Royal Free Hospital (GB)
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2011-12-09
- Volume
- 13
- Issue
- 1
- Pages
- 1-8
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W1987173579
- Cited by
- 39
- References
- 54
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 1 · 2017: 7 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 8 · 2012: 1
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- metformin, heart failure, type 2 diabetes, cardioprotection, cardiac safety, heart failure mortality, drug contraindications
- MeSH terms
- Diabetes Mellitus, Type 2, Heart Failure, Humans, Hypoglycemic Agents, Metformin, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
